id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2023-N-0061-0050,FDA,FDA-2023-N-0061,TAB C - 2013-930-Drug Products-PRIA-FINAL,Supporting & Related Material,Background Material,2024-11-06T05:00:00Z,2024,11,,,2024-11-06T17:02:05Z,,0,0,0900006486800148
FDA-2023-N-0061-0045,FDA,FDA-2023-N-0061,TAB A - 2013-930-Drug Products-Proposed Rule-ORIGINAL,Supporting & Related Material,Background Material,2024-11-06T05:00:00Z,2024,11,,,2024-11-06T17:01:31Z,,0,0,0900006486800149
FDA-2023-N-0061-0049,FDA,FDA-2023-N-0061,TAB B - 2013-930-Drug Products-PRIA-TRACK CHANGE FROM ORIGINAL TO FINAL,Supporting & Related Material,Background Material,2024-11-06T05:00:00Z,2024,11,,,2024-11-06T17:01:59Z,,0,0,0900006486800147
FDA-2023-N-0061-0046,FDA,FDA-2023-N-0061,TAB B - 2013-930-Drug Products-Proposed Rule-TRACK CHANGE FROM ORIGINAL TO FINAL,Supporting & Related Material,Background Material,2024-11-06T05:00:00Z,2024,11,,,2024-11-06T17:01:38Z,,0,0,090000648680014a
FDA-2023-N-0061-0048,FDA,FDA-2023-N-0061,TAB A - 2013-930-Drug Products-PRIA-ORIGINAL,Supporting & Related Material,Background Material,2024-11-06T05:00:00Z,2024,11,,,2024-11-06T17:01:54Z,,0,0,0900006486800144
FDA-2023-N-0061-0047,FDA,FDA-2023-N-0061,TAB C - 2013-930-Drug Products-Proposed Rule-FINAL,Supporting & Related Material,Background Material,2024-11-06T05:00:00Z,2024,11,,,2024-11-06T17:01:44Z,,0,0,090000648680014b
FDA-2023-N-0061-0044,FDA,FDA-2023-N-0061,"Memorandum - Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act (Proposed Rule)",Other,Memorandum,2024-11-06T05:00:00Z,2024,11,2024-11-06T05:00:00Z,,2024-11-06T17:00:18Z,,0,0,09000064867ffe78
FDA-2023-N-0061-0004,FDA,FDA-2023-N-0061,Reference 02 PCAC transcript March 9 2016,Supporting & Related Material,Background Material,2024-03-20T04:00:00Z,2024,3,,,2024-03-20T15:37:08Z,,0,0,0900006486487b7d
FDA-2023-N-0061-0012,FDA,FDA-2023-N-0061,Reference 09 PCAC briefing May 8-9 2017,Supporting & Related Material,Background Material,2024-03-20T04:00:00Z,2024,3,,,2024-03-20T15:47:41Z,,0,0,09000064864886b6
FDA-2023-N-0061-0013,FDA,FDA-2023-N-0061,Reference 10a PCAC briefing Nov 20-21 2017,Supporting & Related Material,Background Material,2024-03-20T04:00:00Z,2024,3,,,2024-03-20T15:48:46Z,,0,0,09000064864886a3
FDA-2023-N-0061-0007,FDA,FDA-2023-N-0061,Reference 05 PCAC transcript Nov 21 2017,Supporting & Related Material,Background Material,2024-03-20T04:00:00Z,2024,3,,,2024-03-20T15:40:06Z,,0,0,0900006486487b80
FDA-2023-N-0061-0001,FDA,FDA-2023-N-0061,"Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act",Proposed Rule,Notice of Proposed Rulemaking (NPRM),2024-03-20T04:00:00Z,2024,3,2024-03-20T04:00:00Z,2024-06-19T03:59:59Z,2024-06-20T01:00:32Z,2024-05801,0,0,090000648648745b
FDA-2023-N-0061-0009,FDA,FDA-2023-N-0061,Reference 07a PCAC briefing March 8-9 2016,Supporting & Related Material,Background Material,2024-03-20T04:00:00Z,2024,3,,,2024-03-20T15:44:38Z,,0,0,09000064864886b3
FDA-2023-N-0061-0006,FDA,FDA-2023-N-0061,Reference 04 PCAC transcript May 8-9 2017,Supporting & Related Material,Background Material,2024-03-20T04:00:00Z,2024,3,,,2024-03-20T15:39:08Z,,0,0,0900006486487b7f
FDA-2023-N-0061-0010,FDA,FDA-2023-N-0061,Reference 07b PCAC briefing March 8-9 2016 errata and addendum,Supporting & Related Material,Background Material,2024-03-20T04:00:00Z,2024,3,,,2024-03-20T15:45:43Z,,0,0,09000064864886b4
FDA-2023-N-0061-0008,FDA,FDA-2023-N-0061,Reference 06 PCAC briefing June 17-18 2015,Supporting & Related Material,Background Material,2024-03-20T04:00:00Z,2024,3,,,2024-03-20T15:41:55Z,,0,0,09000064864886b2
FDA-2023-N-0061-0003,FDA,FDA-2023-N-0061,Reference 01 PCAC transcript June 18 2015,Supporting & Related Material,Background Material,2024-03-20T04:00:00Z,2024,3,,,2024-03-20T15:36:09Z,,0,0,0900006486487b7c
FDA-2023-N-0061-0005,FDA,FDA-2023-N-0061,Reference 03 PCAC transcript Nov 3 2016,Supporting & Related Material,Background Material,2024-03-20T04:00:00Z,2024,3,,,2024-03-20T15:38:12Z,,0,0,0900006486487b7e
FDA-2023-N-0061-0011,FDA,FDA-2023-N-0061,Reference 08 PCAC briefing Nov 3 2016,Supporting & Related Material,Background Material,2024-03-20T04:00:00Z,2024,3,,,2024-03-20T15:46:39Z,,0,0,09000064864886b5
FDA-2023-N-0061-0002,FDA,FDA-2023-N-0061,Reference Summary List for Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under sections 503A and 503B,Supporting & Related Material,Background Material,2024-03-20T04:00:00Z,2024,3,,,2024-03-20T15:34:54Z,,0,0,0900006486487b7b